Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.63 |
| ▸ | IKBKB | O14920 | 8/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087548 | 0.99 | IKBKB (0.64) | CHEK1IKBKBMAP3K7BACE1LTA4H | |
| SCHEMBL1383089 | 0.91 | CHEK1 (0.75) | CHEK1IKBKBMAP3K7LTA4HHRH3 | |
| SCHEMBL7478158 | 0.91 | IKBKB (0.60) | CHEK1IKBKBMAP3K7KDM4E | |
| SCHEMBL4093365 | 0.90 | CHEK1 (0.73) | CHEK1IKBKBMAP3K7LTA4H | |
| SCHEMBL4085764 | 0.82 | MAP3K7 (0.53) | CHEK1IKBKBMAP3K7KDM4EMEN1 | |
| SCHEMBL7471787 | 0.82 | MAP3K7 (0.62) | CHEK1IKBKBMAP3K7KDM4EGAA | |
| SCHEMBL4088491 | 0.81 | MAP3K7 (0.54) | CHEK1IKBKBMAP3K7KDM4EMEN1 | |
| SCHEMBL4092536 | 0.80 | IKBKB (0.71) | CHEK1IKBKBMAP3K7 | |
| SCHEMBL4086891 | 0.79 | IKBKB (0.69) | CHEK1IKBKBMAP3K7KDM4E | |
| SCHEMBL1383137 | 0.78 | IKBKB (1.00) | CHEK1IKBKBMAP3K7KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358376-B2 | Substituted Thiophene compounds | ASTRAZENECA AB (SE) | 2008-04-15 | — | — | US | claimed |
| EP-1261600-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | claimed |
| US-20020107252-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | US | claimed |
| US-20090181962-A1 | Substituted thiophene compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2009-07-16 | — | — | US | disclosed |
| US-7358376-B2 | Substituted Thiophene compounds | ASTRAZENECA AB (SE) | 2008-04-15 | — | — | US | disclosed |
| EP-1261600-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| US-20020107252-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181962-A1 | Substituted thiophene compounds | ABCG2, SULT1E1, TPMT | CHEK1 2784/4885IKBKB 3065/4885MAP3K7 3851/4885 |
| US-20020107252-A1 | Novel Compounds | UGT1A1, CYP1B1, CYP1A1 | CHEK1 3060/4885IKBKB 2413/4885MAP3K7 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.